ArticleNaunyn-Schmiedeberg's archives of pharmacology2025
A novel cycloastragenol-encapsulated carboxymethyl chitosan-silk fibroin hydrogel combined with sucralfate alleviates MNNG-induced chronic atrophic gastritis by targeting HIF-1α and VEGF signaling pathways.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In order to treat chronic atrophic gastritis (CAG) caused by N-methyl-N'-nitro-N-nitrosoguanidine (MNNG), the present study successfully fabricated a carboxymethyl chitosan (CMC)-silk fibroin (SF) hydrogel encapsulating cycloastragenol (Cyl) and sucralfate (SC) (Cyl-SC@SF/CMC). This represents a substantial improvement in drug delivery and therapeutic efficacy. The SEM analysis shows the porosity of fabricated Cyl-SC@SF/CMC revealed a network of pores inside the hydrogel. Thermogravimetric and rheological investigations confirmed that the hydrogel was the structure of SF and CFC forming intermolecular hydrogen bonds. A model was developed to stimulate the impact of MNNG on gastric epithelial cells. Furthermore, cell counting kit-8 (CCK-8) assay was employed to evaluate the viability and proliferation of MNNG induced CAG in GES-1 after exposed to fabricated Cyl-SC@SF/CMC hydrogels. The results displayed that Cyl-SC@SF/CMC is superior than SC@SF/CMC in promoting the growth of GES-1 cells while simultaneously reducing MNNG-triggered damage to GES-1 cells and mitochondrial dysfunction. Moreover, cell migration and invasion analysis revealed that Cyl-SC@SF/CMC significantly enhanced migration and suggesting its role in tissue repair and regeneration. Moreover, in CAG rats, Cyl and SC in the hydrogel exerted therapeutic effects by considerably reducing histological damage in gastric tissues as evidenced by histopathological examinations. Furthermore, the pharmacokinetics analysis showed that Cyl-SC@SF/CMC formulation exhibited a higher area under the curve (AUC
Indexed as
Identifiers
40488849What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.